Trial Profile
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients (pPCL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2018
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary)
- Indications Plasma cell leukaemia
- Focus Therapeutic Use
- 18 Jan 2018 New trial record